HCPCS code J1630: Haloperidol injection billing guide

Key takeaways

HCPCS code J1630 covers an injection of haloperidol lactate, and one billing unit means one 5 mg increment.

A 10 mg dose bills as 2 units, so reporting 5 units for 5 mg overstates the claim five times over.

Medicare Part B pays J1630 at ASP plus 6% in the office, and CMS refreshes that price every quarter.

Medicare and Medicaid claims need the 11-digit NDC off the vial, plus modifier JW or JZ on every line.

J1631 is the decanoate code and counts per 50 mg, which is where the costly 10x unit mix-up starts.

HCPCS code J1630 pays for an injection of haloperidol lactate, up to 5 mg per unit. That unit definition is the whole story. A 5 mg dose is one unit and a 10 mg dose is two. Read the code as per-milligram instead and you bill five times what the claim is worth.

Haloperidol lactate is cheap, so the money at stake on any single claim is small. Repeat the error across a busy psychiatric service and it stops being small. The sections below work through the descriptor, Medicare’s payment math, the NDC and modifier rules, and how J1630 differs from J1631.

HCPCS code J1630 covers the lactate, not the decanoate

HCPCS code J1630 is maintained by the Centers for Medicare and Medicaid Services (CMS) as part of the HCPCS Level II code set.

The official long descriptor reads: Injection, haloperidol, up to 5 mg. CMS added J1630 effective January 1, 1986, and the code stays active for 2026 with no termination date.

One detail decides the code: J1630 applies to the lactate formulation only. Haloperidol decanoate is coded separately as J1631.

Practices that stock both formulations are the ones that get audited on this. The two vials sit on the same shelf, and the charge template rarely tells them apart.

Haloperidol is a first-line injectable for acute agitation

Haloperidol (brand name Haldol, Janssen) is a first-generation antipsychotic in the butyrophenone class. It blocks dopamine D2 receptors in the mesolimbic pathway, which brings down positive psychotic symptoms.

Emergency departments and inpatient psychiatric units keep it stocked because it works fast by the intramuscular route and sits on almost every formulary.

FDA-approved indications for injectable haloperidol include the clinical scenarios where J1630 usually applies:

• Schizophrenia, whether an acute exacerbation or maintenance by the IM route
• Acute agitation linked to schizophrenia or bipolar disorder
• Tourette’s disorder, for severe tics that oral therapy has not controlled
• Behavioral control in severe psychiatric symptoms that call for rapid tranquilization

Off-label use is common in practice, particularly for delirium in the ICU and for chemotherapy-induced nausea. When you bill an off-label administration, make sure the linked ICD-10 code reflects a medically necessary indication.

The note also has to spell out the clinical reasoning. Payers look harder at off-label drug claims than at any other line in this family.

The ICD-10 codes that carry medical necessity for J1630

Every J1630 claim needs an ICD-10-CM diagnosis code that establishes medical necessity. Payers reject injectable antipsychotic claims most often when the diagnosis on the line does not support the drug that was given.

The table below lists the codes paired with J1630 most frequently on Medicare and commercial claims.

R45.1 is the pragmatic choice in an emergency department when no psychiatric diagnosis is confirmed yet. Once the workup lands on something definitive, use that code on the follow-up billing instead.

Payers can ask for documentation showing the diagnosis was recorded alongside the administration rather than added afterwards. Each code in that table carries its own documentation quirks, which our ICD-10-CM code guides cover one by one.

Medicare pays J1630 on ASP, and ASP moves every quarter

Under Medicare Part B, physician-administered drugs like J1630 are paid on the Average Sales Price (ASP) methodology. The formula is ASP plus 6%, where the 6% is meant to cover acquisition, storage, and handling.

CMS republishes ASP pricing files quarterly, so the allowed amount for J1630 changes four times a year. Check current rates in the CMS Physician Fee Schedule lookup tool before you submit the first claims of a new quarter.

Payment also moves with the place of service. Hospital outpatient departments fall under the Outpatient Prospective Payment System (OPPS), which pays on a different basis than the physician office.

The same 5 mg injection can therefore land at two different allowed amounts depending on where the patient received it.

The rate follows the place of service

Haloperidol lactate is a low-cost generic, so ASP plus 6% on J1630 is a modest number. Practices running high volumes of psychiatric injections should compare acquisition cost against ASP payment each quarter. That is the only way to know whether buy-and-bill still washes its face for this drug.

Buy-and-bill or 340B, and where the margin sits

Buy-and-bill means the practice purchases haloperidol lactate from a wholesaler, administers it, then bills J1630 to the payer. Medicare pays ASP plus 6%. The difference between acquisition cost and that payment is the practice’s return on the drug.

Covered entities under the 340B Drug Pricing Program, administered by HRSA, buy haloperidol lactate at reduced 340B ceiling prices. They still bill J1630 at the standard rate, which widens the margin.

Since January 1, 2025, 340B covered entities report modifier TB on the drug line, replacing the retired JG modifier. The compliance conditions that come with the discount are strict:

• The patient must meet the 340B patient eligibility criteria for that covered entity.
• 340B drugs must not reach ineligible patients, and duplicate discounts must not reach Medicaid.
• Documentation has to confirm the patient’s 340B-eligible status at the time of administration.
• Medicaid patients need separate tracking under the 340B exclusion rules.

Practices outside the program bill J1630 from wholesale acquisition cost or contract pricing and receive ASP plus 6%.

Because haloperidol lactate’s ASP is low, the 340B benefit on this particular drug is thin while the compliance burden is identical to a high-cost biologic. Only entities that have confirmed covered entity status with HRSA should apply 340B pricing to J1630.

The NDC has to match the vial in your hand

CMS requires an NDC (National Drug Code) on the claim line alongside HCPCS code J1630 for Medicare and Medicaid. The NDC names the exact product and package given, which is how CMS ties the claim back to drug pricing.

Missing or wrong NDCs are the leading reason J1630 claims reject at submission. Capture the number at the point of administration, not later at charge entry.

Several companies manufacture haloperidol lactate, and the NDC changes with the manufacturer and the package size. Products from Hikma Pharmaceuticals, Pfizer, and Fresenius Kabi all turn up as 5 mg/mL vials.

Because repackaging and supplier changes move these numbers, read the NDC off the vial that was used. Billing from memory or from a saved template is how the wrong number gets on the claim.

Run this checklist before a J1630 claim goes out

Billing J1630 takes more than dropping the code onto a charge line. The claim has to carry the dose in units and the right place of service. It also needs the NDC off the vial and a diagnosis that supports the drug. Work down this list before the batch leaves.

1. Units: One unit means one increment of up to 5 mg. A 5 mg dose is 1 unit. A 10 mg dose ordered in a single encounter is 2 units. Never report a fractional unit.
2. Place of service: Use the POS code for where the injection happened. That means 11 for the office, 22 for a hospital outpatient department, and 23 for the emergency department. A POS mismatch is a standing audit flag.
3. Modifiers: Since July 1, 2023, CMS requires JW or JZ on every claim for a drug supplied in a single-dose vial. Report JW with the discarded amount when part of the vial is wasted. Report JZ when none of it is discarded. 340B covered entities add modifier TB, which replaced JG on January 1, 2025.
4. NDC reporting: Report the 11-digit NDC, the unit of measure qualifier, and the quantity administered. Medicare and Medicaid require it, and most commercial payers have followed.
5. Medical necessity: The record needs the physician order and the clinical indication tied to an ICD-10-CM code. It also needs the administration entry with time, route and dose, plus the credentials of whoever gave the injection.

Units cause more J1630 rejections than any other field on that list, and the reason is easier to see side by side with J1631.

Five mistakes that get J1630 claims denied

J1630 denials cluster around five mistakes. Each one is visible on the claim before it goes out, which makes them cheap to catch and expensive to leave alone.

• Units billed per milligram: A 5 mg dose entered as 5 units overstates the claim five times over and invites an overpayment demand. One unit is one 5 mg increment.
• Missing NDC: J1630 without an NDC rejects automatically on Medicare and Medicaid claims. Capture it from the vial at the time of administration.
• Wrong place of service: POS 11 on a drug given in the emergency department pushes the claim onto the wrong fee schedule. The setting decides how the line gets paid.
• Diagnosis that does not support the drug: A wound care diagnosis on a psychiatric injection triggers a medical necessity denial. The linked ICD-10-CM code has to reflect why haloperidol was ordered.
• Inpatient bundling: Drug costs during a Part A inpatient stay sit inside the DRG payment. Billing J1630 to Part B for those days duplicates what the hospital was already paid.

Here is what a clean J1630 line looks like in practice. A patient in the emergency department receives 10 mg of haloperidol lactate IM for acute agitation. The claim goes out carrying:

• J1630 with 2 units, because 10 mg is two 5 mg increments
• POS 23 for the emergency department
• The 11-digit NDC from the vial, with the N4 qualifier and the ML quantity
• Modifier JZ, because none of the vial was discarded
• F29 as the linked diagnosis, with the workup still pending

Every field on that line traces back to something the clinician recorded at the bedside. When one of them has to be reconstructed from memory at charge entry, that is the field that ends up wrong.

J1630 vs J1631: acute dose versus monthly depot

The most common code confusion in haloperidol billing sits between J1630 and J1631. Both cover haloperidol, but they describe different formulations with different clinical jobs, dosing units, and payment profiles.

J1631 counts per 50 mg while J1630 counts per 5 mg, so a mix-up moves the billed units by a factor of ten.

The clinical rule is simple. If the drug is calming an episode happening right now, use J1630. If the patient is getting a scheduled depot injection for long-term maintenance, use J1631.

Practices that stock both and do not separate them in the medication administration record end up making this error on a schedule.

Other antipsychotic J-codes worth knowing

Psychiatric and emergency billing runs into the wider antipsychotic J-code family often, and several of these codes are routinely mixed up with each other.

Brand names are the usual culprit, because one molecule can carry a short-acting code and a long-acting code that look nothing alike. The AAPC HCPCS code lookup is a useful crosscheck alongside this table.

Formulation decides the code in this family, not the drug name. Aripiprazole alone occupies two codes with a fourfold difference in unit size.

Check the vial against the descriptor whenever a new drug goes into the charge template, and again whenever a supplier changes.

How claims management software keeps J1630 lines consistent

Plenty of practices still rebuild the J1630 line by hand. Someone opens the administration record, types the code, works out the units, then copies the NDC off the vial label into the claim. Each of those steps is a chance to transpose a digit.

Practice management software like Pabau shortens that journey. Our claims management software pre-fills the claim form from the client record. The code attached to the service lands on the charge line, and the recorded diagnosis seeds the ICD-10 slot.

Full ICD-10-CM and HCPCS lookup libraries sit behind a search icon, so a coder can check J1630 against J1631 without leaving the claim. Pabau also confirms that required claim fields are complete before the send button unlocks. US claims route through Claim.MD, so eligibility checks and remittance posting sit alongside the record.

Your team still decides the units, the modifier, and the NDC on the line. Pabau does not choose those for you, and no software should. What it removes is the retyping between the treatment note and the claim. That handoff is where transcription errors get in.

Build the J1630 line from the treatment record

Pabau pre-fills the claim from the clinical record and checks that required fields are complete before you submit. Your billing team keeps control of the units, the modifier, and the NDC.

Book a demo

Conclusion

J1630 is a small code with an outsized error rate, and the fix nearly always sits upstream of the claim. Set the charge template to count in 5 mg increments once and the unit errors stop repeating. Capture the NDC at the bedside rather than at charge entry and the rejections stop with them.

The trade-off worth remembering is that haloperidol lactate is cheap. Chasing a corrected J1630 claim costs more staff time than the claim is worth. The money is in getting the line right the first time, on a drug nobody thinks twice about.

Book a demo to see how Pabau carries the drug, dose, and diagnosis from the treatment note onto the claim form.

Continue your research

Want to see why your J-code claims keep bouncing? Denial management in healthcare walks through the rejection patterns that repeat and how to close them off.

Not sure what a drug administration superbill should capture? Superbill documentation best practices sets out the fields that keep a charge line defensible.

Chasing a higher first-pass acceptance rate? What makes a clean claim breaks down the elements a payer checks before a claim is adjudicated.

Billing high-scrutiny injectable drugs regularly? Medical billing compliance covers the documentation standards auditors apply to injectable claims.

Frequently asked questions